Aims: To review 'Diabetes Control and Complications Trial (DCCT)-aligned' HbA 1c reporting in UK, use of individual/network equations relating IFCC calibration to 'DCCT alignment', and whether HbA 1c in the presence of variant haemoglobins is, according to manufacturers, suitable for current, clinical guidelines.
Introduction
National guidelines issued in the UK by the National Institute for Health and Clinical Excellence (NICE: www.nice.org.uk) for treatment of type 2 diabetes 1 and more recently type 1 diabetes, 2,3 along with the new General Medical Services 2 (GMS2) contract for general practitioners (GPs) 4 include targets for haemoglobin A 1c (HbA 1c ). They recommend that HbA 1c values be aligned to those in the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS). HbA 1c is now used for assessing the risk of diabetic complications as well as for monitoring glycaemic control. As a consequence, the number of HbA 1c requests sent to laboratories has increased markedly and the spectrum of patients presenting for testing has widened considerably. 5 In patients with variant haemoglobins, anaemia or abnormal red blood cell turnover, HbA 1c measurement may not be appropriate. This was not an issue in the DCCT 6 as patients with variant haemoglobins were excluded, nor in the UKPDS 7 as protocol-led changes in glucose lowering therapy were based on fasting plasma glucose (FPG) rather than HbA 1c . HbA 1c was reported in a small number of UKPDS patients with variant haemoglobins according to the then current recommendations of the manufacturers.
The prevalence of particular haemoglobin variants is increased in some ethnic groups. The ongoing neonatal screening programme for London and the South East has identi¢ed approximately 7000 haemoglobinopathies in 410,000 neonates (1.7%), with the most common heterozygotes being AS (57%), AC (14%), AD Punjab(Los Angeles) (8.6%), AE (7.1%) and homozygotes SS (1.8%). 8 According to the 2001census, 9 the minority ethnic population in the UK numbered 4.6 million or 7.9% of the total population with half Asian of Indian, Pakistani, Bangladeshi or other Asian origin and a quarter describing themselves as Black, from the Caribbean, Africa or other parts of the world. These groups were more likely to live in England, with 45% living in the London region, 13% in the West Midlands, 8% in the South East and North West, and 7% in Yorkshire and the Humber region. 10 The high prevalence of variant haemoglobins together with the increased incidence of type 2 diabetes in these ethnic groups is signi¢cant when monitoring glycaemic control.
Most methods for HbA 1c measurement in UK laboratories or for point of care testing (POCT) are based on chromatography (a⁄nity or high/low pressure, ion exchange [IE], liquid chromatography) or immunochemistry. 'DCCT-aligned' HbA 1c values will have been obtained by manufacturers working with the National Glycohemoglobin Standardization Program (NGSP) (www.missouri.edu/$diabetes/ngsp). This scheme, set up in the US with the American Diabetic Association and American Association for Clinical Chemistry after the DCCT, provides certi¢cation for an instrument/ method after assessment of accuracy and imprecision according to pre-set criteria for manufacturers and also for individual laboratories. 11 The recent European Community InVitro Diagnostic (EC IVD) directive requires all laboratory methods to be calibrated using the highest level reference method available. 12 Since December 2003, all HbA 1c methods have been calibrated using the newly available, International Federation of Clinical Chemistry (IFCC) reference method. 13 This involved preparation of hexapeptides of HbA 1c and HbA 0 , separation in patients' samples by reverse-phase HPLC and quanti¢cation by either electron-spray ionization-mass spectrometry or capillary electrophoresis. 13 The reference method is mainly used to assign values to secondary standards derived from blood cells containing HbA 1c . Results from the IFCC reference method correlate well with 'DCCT-aligned' HbA 1c , but are lower by 1.0--2.0% HbA 1c . . 14 However, since 'DCCT-aligned' HbA 1c results will continue to be reported in the UK for the present, 15, 16 manufacturers are responsible for converting IFCC HbA 1c results (www.ifcchba1c.com) to 'DCCTaligned'equivalents for each of their methods.
Most current literature relates to whether separation of HbA 1c by chromatography in the presence of a variant haemoglobin 17, 18 is ideal or if results from immunoassays for glycated haemoglobins such as S or C can be obtained from the epitope/s of the antibody and reported as 'HbA 1c '. Interpretation of data from the early 1990s on reference ranges from di¡erent assays in a small number of non-diabetic patients with variant haemoglobins led researchers to conclude that HbA 1c should not be reported in these patients if diabetic. 19 In this paper, we report on a questionnaire circulated to nine manufacturers of analytical systems for HbA 1c used in the UK to establish if methods were certi¢ed by NGSP and whether manufacturers used individual equations derived for their equipment for reporting 'DCCTaligned' HbA 1c after calibration with the IFCC reference method or the master equation obtained by the NSGP and IFCC networks from their sample comparisons. We also requested information on whether HbA 1c values comparable with national guidelines could be reported on patients with variant haemoglobins, the relationship of glucose to HbA 1c and reference ranges in such patients.
Methods

Survey participants
Analytical systems for HbA 1c were selected from participants listed in UK NEQAS reports for glycated haemoglobins (Table1). A questionnaire was circulated to nine manufacturers of the most commonly used assays in the clinical laboratory and at point of care for both service care and research purposes. The information was required for a workshop entitled 'Glycated haemoglobin analysis in patients with haemoglobin variants' held in May 2004. Manufacturers were contacted again in December 2004 to con¢rm that the information was still current; some manufacturers provided more information at that time and in December 2005.
Questionnaire
Form A asked for details of each instrument and kit, and included questions on certi¢cation by NGSP, whether users reported 'DCCT-aligned' results, what equation was used for conversion of HbA 1c results from IFCC calibration to 'DCCT alignment', reference ranges and their origin, and whether each analytical system was for laboratory use, POCT or both.
Form B requested information on identi¢cation of haemoglobin variants by analytical systems and recommendations for reporting of HbA 1c in the presence of variants (i.e. heterozygotes AS, AC, AD and AE, homozygotes SS, CC, DD and EE, and also fetal haemoglobin, carbamylated haemoglobin, methaemoglobin and labile HbA 1c [Schi¡ base]). Manufacturers were also asked to suggest other factors that might interfere with the measurement of HbA 1c and to provide information on the relationships of blood glucose to HbA 1c in the presence of a variant haemoglobin for comparison with the relationships published for the DCCT, mean plasma glucose from pro¢les 20 or FPG in the UKPDS. 21 They were also asked about advice o¡ered to users for reporting HbA 1c in the presence of a variant/unusual haemoglobin.
Analysis
The transfer of data from the questionnaire to tables was checked by a second person. The tables were circulated to the manufacturers at the end of 2004 and in some cases data were updated. The ¢nal tables were circulated to the manufacturers in December 2005 and con¢rmed as correct.
Results
All nine companies replied; see Table 1 for the HbA 1c methods surveyed.
Details of manufacturers surveyed -information on methods and reference intervals
High throughput IE HPLC equipment for HbA 1c measurement is provided by three manufacturers with shorter run times for measurement of HbA 1c only, in the order of 2 min, which is advantageous for patients with diabetes given the volume of requests, and longer run times of 7 min for full analysis of variant haemoglobins. Formal identi¢cation of these requires a second con¢rmatory test, such as the sickling test for AS, usually performed in a haematology laboratory. Programs intended primarily for identi¢cation of variants with longer run times do not necessarily include calibration and therefore do not always report 'DCCT-aligned' HbA 1c . IE HPLC can be used in a satellite laboratory or diabetic clinic if operated by suitably quali¢ed sta¡ with performance monitored by standard laboratory internal quality control (IQC) and external quality assessment (EQA).
Immunochemical methods are available from four manufacturers, some requiring dedicated equipment and others routine automated analysers for general clinical chemistry. Some instruments utilising 
UK NEQAS for HbA 1c
Data (December 2004) from UK NEQAS for a whole blood specimen, Figure 1 , showed that 95% of HbA 1c methods in the scheme reported 'DCCT-aligned' results and 5% (12/265) non-aligned results. The mean value for the non-aligned group was approximately 0.6% HbA 1c lower than the 'DCCT-aligned' group mean at a level of 8.11% HbA 1c . Although 'DCCT-aligned' HbA 1c can be reported from all methods surveyed, two manufacturers reported that not all UK hospitals using their equipment reported 'DCCT-aligned' HbA 1c , (Table 1) . Of the participants submitting DCCT-aligned HbA 1c results, 64% (158/253) used high throughput IE HPLC analysers, predominantly based in laboratories or satellite laboratories in diabetes centres, 27% (69) used immunochemical techniques and 3% (7) used a⁄nity chromatography; 20% (50) used immunochemically based systems suitable for POCT ( Figure 1 ).
Information returned by manufacturers on reporting of 'DCCT-aligned' HbA 1c , conversion from IFCC values and reference intervals
All methods were certi¢ed by the NGSP at the level of the manufacturer (Table 1) with accuracy currently de¢ned so that 95% con¢dence intervals (CI) of the di¡erences between the method being certi¢ed and NGSP results are within 1.0% HbA 1c . In practice (Figure 1 ), HbA 1c values from the various 'DCCT-aligned' analysers, with a mean value of 8.11%, agreed well with the corresponding DCCT value of 7.97% obtained by the scheme organizers. The current requirement for imprecision involves a within laboratory coe⁄cient of variation (CV) of o4% for an analyser over several days. Inter-laboratory CVs for the various di¡erentmethod groups providing 'DCCT-aligned' values in this UK NEQAS circulation ranged from 1.6% to 5.7%. Of the nine manufacturers, three reported that they use individual equations derived for their particular analytical systems for conversion of results from IFCC calibration to 'DCCT-aligned' and the remaining six use the master equation relating the IFCC and NGSP networks ( Table 1) .
Most manufacturers reported an upper limit of about 6% 'DCCT-aligned' HbA 1c for their reference intervals. Information was either derived from literature produced by the DCCT or data obtained by the manufacturer for their particular analytical systems ( Table 1) . One manufacturer reported both a 'DCCTaligned' and IFCC reference interval with the caveat that each laboratory should determine its own reference interval.
Effect of presence of variant haemoglobins on HbA 1c
The information below was provided by the manufacturers of the individual instruments/kits. 
Measured by IE HPLC in the laboratory
Measured for POCT
Portable analysers
Of the results in UK NEQAS, 18% come from one portable analyser (DCA 2000), an immunochemical method commonly used for POCT (Figure1). However, it is likely that not all these analysers in current use are monitored by EQA schemes. The monoclonal antibody used by Bayer is speci¢c for the N-terminal amino acids of the glycated HbA1c b-chain whether normal or variant haemoglobin if similar. It measures both HbA 1c and total haemoglobin, and reports percentage HbA 1c so the presence of a haemoglobinopathy cannot be detected by this analyser (Table 3 ). Since haemoglobins S and C, have the same structure as HbA 1c for the ¢rst few amino acids, the DCA measures these glycated variants and reports them as 'HbA 1c ' (Table 3 ). Patients homozygous for S and C can have erythrocyte life spans shorter than normal, which could lower the percentage of glycated haemoglobin reported in these patients. 19 The DCA does not detect glycated HbF. If HbF is 410%, HbA 1c results will be a¡ected and may possibly be lower than normal. Acetylated and carbamylated haemoglobin are not detected by the DCA and the labile Schi¡ base intermediate not measured. The manufacturers recommend that HbA 1c can be reported over the total haemoglobin range 7--24 g/dL but that in patients with severe anemias, polycythemia or other conditions causing abnormal total haemoglobin levels or turnover, glycaemic control should not be monitored by HbA 1c . Again, as for the larger laboratory analysers using immunochemistry, HbA 1c results from the DCA for patients with variant haemoglobins should be treated with caution as no information is available on the relationship of glucose to HbA 1c in these patients and no reference ranges have been established. Another small analyser mainly for POCT, the Hae-maQuant Glycosal HbA 1c system, uses boronate a⁄nity chromatography. The company has tested the e¡ects of haemoglobins AS, AC, AD, AE and carbamylated haemoglobin on the system and quoted information from literature for the other haemoglobins. Other small POCT analysers based on IE LPLC and IE HPLC, that can detect the presence of variant haemoglobins depending on their particular limitations, are available for measurement of HbA 1c , but have not been reviewed for this paper. 22 
Cartridges
The disposable Metrika A1cNow meter (similar in size to a pedometer), will most likely report an error code in the presence of SS, CC and SC ( Table 3 ). The antibody for Metrika A1cNow binds to the ¢rst six amino acids of the N-terminal haemoglobin b-chain sequence.'HbA 1c ' results for glycated haemoglobin in patients with DD and EE will possibly be low. If HbF is present, the results from the cartridge must be interpreted with caution, as this method cannot identify raised HbF.
Questions on relationship of HbA 1c to glycaemia and reporting strategy in presence of a variant haemoglobin
When asked to provide information on the relationship of glucose to HbA 1c in the presence of a variant haemoglobin, none was available. One company providing IE HPLC equipment pointed out that if a variant and its glycated fraction have a di¡erent lifespan (from HbA 1c ), this could lead to the underestimation of glycaemic exposure in patients. In these circumstances, the exclusion of the variant from the calculation of HbA 1c in heterozygous patients could be considered.When asked what advice would be o¡ered to users on monitoring glycaemia if HbA 1c could not be reported, one company suggested using an alternative technique and contacting their customer advice service, two companies suggested fructosamine and another emphasized that results could be a¡ected by the presence of a haemoglobinopathy.
Discussion
Much has been written recently about HbA 1c since the publication of various guidelines for the treatment of diabetes 23--26 including its possible use for diagnosis. 27, 28 All nine methods surveyed for this paper (December 2005) are certi¢ed by NGSP as comparable to the DCCT and UKPDS with UK EQA (UK NEQAS and WEQAS) schemes showing 95% of methods reporting 'DCCT-aligned' HbA 1c . HbA 1c will continue to be reported as 'DCCT-aligned' in the UK 16 until the inter- national committee representing the diabetes and clinical chemistry communities produces a global strategy on reporting. 29 Concern has been raised about introducing the lower IFCC reference range given the Swedish experience when glycaemic control in the population worsened following the introduction of an assay with a lower reference range. 30 The UK HbA 1c Standardisation Advisory Group, representing health care professionals and patient groups, 14, 15 will be reconvened by Diabetes UK to decide how global decisions on reporting 29 will be implemented in the UK and organize an extensive education program to improve patients' understanding of HbA 1c beforehand.
Since the IFCC HbA 1c reference method was introduced for calibration in December 2003, one-third of manufacturers (both for Europe and worldwide) report use of individual equations derived for their equipment for conversion to NGSP (Table 1) , with the others using the master equation relating the IFCC and NGSP networks. 31 At this time, either approach to conversion of results is acceptable. The choice of equation could be important for long term, ongoing research studies where small di¡erences in HbA 1c are expected, since this one-o¡ change in calibration could have resulted in a small change in bias within the criteria set by NGSP. If in doubt, researchers should contact the manufacturers of their analytical systems. UK EQA schemes should have su⁄cient data to detect any changes in bias of analytical systems due to the new calibration procedures and report accordingly at their next annual meetings.
The NICE guidelines issued in September 2004 for treatment of adult patients with type 1 diabetes recommend use of 'DCCT-aligned' HbA 1c and include a comment that 'diagnosis may be supported by a raised HbA 1c ' although HbA 1c alone is not recommended for diagnostic purposes. They recommend clinical monitoring of glycaemic control by high precision 'DCCTaligned' methods of HbA 1c performed every two to six months, with site-of-care measurement or measurement before clinical consultation, and communication of HbA 1c to the patient after each measurement. Given the targets recommended for HbA 1c (e.g. 'o6.5% to minimize risk of developing diabetic complications') in the new IDF guidelines, 32 it is important that providers of analytical services, particularly those outside the traditional laboratory, are aware of the limitations of their method when variant haemoglobins or other factors such as anaemia or abnormal red blood cell turnover that a¡ect HbA1c results are present. Since the operation of any technology is a partnership between the clinical laboratory and providers of analytical systems, we reviewed, for presentation at a national clinical chemistry workshop, information available on HbA 1c reporting from manufacturers with the help of their technical support teams.
As type 2 diabetes is prevalent in populations with a high incidence of haemoglobinopathies, the provision of reliable results for HbA 1c for management of hyperglycaemia is a dilemma facing all those measuring HbA 1c . Very low or high results for HbA 1c should be treated with caution since some haemoglobin variants can lead to either falsely high or low results, depending on the technique used, 33, 34 which could a¡ect the management of the patient. All HbA 1c results should be interpreted along with other measures of glycaemic control such as home blood glucose monitoring (HBGM), random blood glucose (RBG), FPG, continuous blood glucose monitoring, glucose tolerance test results or fructosamine, and the relevant clinical details.
Over 900 haemoglobin variants have now been iden-ti¢ed; for on-line details see http:/globin.cse.psu.edu/ globin/hbvar. IE HPLC detects the presence of many but not all variants that lead to spurious results for HbA 1c . Some very rare haemoglobin variants such as Camperdown haemoglobin (b 104 (G6) Arg--Ser) co-elute with HbA 1c on IE HPLC giving falsely high results 34 or, in the case of haemoglobin Marseille-Long Island, give vastly di¡erent results from di¡erent techniques as this variant is not recognized by some antibodies. 36 No result for HbA 1c is possible from IE HPLC for homozygous patients or heterozygous patients such as SC; raised HbF can also interfere with results. Since there is no published information on monitoring glycaemic control using HbA 1c in patients with variant haemoglobins in the major clinical trials 37 and little data available for reference intervals for such patients, UK laboratories either decline to report IE HPLC HbA 1c in heterozygous patients if chromatographic separation is ideal or report HbA 1c with a comment stating that 'users should interpret results with caution as they may not be comparable to data in current clinical guidelines'.
Immunochemistry is employed on routine clinical chemistry analysers in some laboratories and smaller portable analysers for POCT. The presence of variant haemoglobins cannot be detected using immunoassay; raised HbF can also interfere with HbA 1c measurement. Glycated haemoglobins such as S and C are reported as 'HbA 1c ' if a result can be obtained from the particular antibody depending on the epitope/s (Tables 2 and 3) . It is therefore advisable to check the patient's history for the presence of a variant haemoglobin if using immunochemical techniques. Referral to a haematology laboratory may be necessary to identify variants. In a few laboratories in the UK, the presence of a variant haemoglobin is recorded on the laboratory computer system so that if HbA 1c is requested for such a patient, an alternative strategy for monitoring glycaemic control is suggested. Perhaps this approach should be copied. In addition, it might be useful if raised HbF Individual clinical biochemistry laboratories should provide an alternative strategy (with co-operation from other laboratories if required) for monitoring glycaemic control if variant haemoglobin present, very high HbF, anaemia or abnormal red blood cell turnover. Fructosamine and glycated albumin indicate glycaemic status over the preceding 2--3 weeks, likewise FPG the previous few days. Information on the relationship of 'DCCTaligned' HbA 1c to fructosamine is sparse, with no agreed strategy for comparison of results. 38 Reference ranges for both analytes have been reported for non-diabetic subjects, age-matched to UKPDS patients with type 2 diabetes, 39 and also HbA 1c ranges for the di¡erent ethnic groups in UKPDS at diagnosis of diabetes. 40 Fructosamine is not an ideal substitute for HbA 1c because of the di¡erent half lives of haemoglobin and albumin, and the lack of evidence relating fructosamine rather than HbA 1c to complications of diabetes. 41--46 The focus of HbA 1c reporting by manufacturers and in scienti¢c papers has changed since the introduction of patient-centred targets for HbA 1c , from whether HbA 1c and other glycated haemoglobins such as S or C can be detected, separated or measured by a particular method, 17, 18 to whether the ensuing HbA 1c result is comparable with targets for glycaemic control in national guidelines. 1--4,47 Scienti¢c papers published in 2005 after this questionnaire indicate that HbA 1c results for patients with S and C traits from a⁄nity chromatography and the IFCC mass spectrometry reference method are similar, 48 but that results from 11 di¡erent methods commonly used in laboratories and for POCT (compared with a⁄nity chromatography) vary considerably with clinically signi¢cant di¡erences. 49 For a⁄nity chromatography, the only information on the relationship of glucose to HbA 1c forwarded by the manufacturers was in patients without haemoglobinopathies. 50 Data on glycated haemoglobin from the early 1990s in non-diabetic patients with S and C variants shows that results di¡er depending on the a⁄nity chromatography system used. 19 
Flow chart for monitoring glycaemic control in patients with diabetes
Following discussion with local clinicians on the limitations of HbA 1c reporting, we have drawn up a simple £ow chart for possible use in clinics, Figure 2 . If the patient is known not to have variant haemoglobin or other factors a¡ecting HbA 1c measurement, any analytical technique can be used in the laboratory or at POCT. In patients at low risk, care should be taken to ensure that HbA 1c results are in line with blood glucose. Most queries about the possibility of variant haemoglobin arise when there is a discrepancy between HbA 1c and the patient's home blood glucose monitoring. In these circumstances, glucose measurements should be con-¢rmed by investigating the performance of the glucose meter, requesting random blood glucose in the clinic, or, FPG or fructosamine from the laboratory. The HbA 1c result should be investigated using another method of HbA 1c measurement, preferably IE HPLC or by referral to haematology for detection/identi¢catoion of any variant haemoglobin.
If the patient with diabetes is at high risk of the HbA 1c result being a¡ected because of the clinical situation, their ethnicity or geographical location, HbA 1c should be measured initially by IE HPLC (or LPLC) to detect the presence of any variant haemoglobin or a blood sample sent to haematology to identify any variant. In this NHS Trust, given the ethnic diversity of the population, fructosamine is recommended for monitoring glycaemia in patients with variant haemoglobins although its limitations are recognized. HbA 1c results from IE HPLC analysers in the hospital laboratory and Diabetes Resource Centre are not reported in heterozygous patients because of the lack of information on glycation rates in patients with variant haemoglobins and their increased risk of anaemia or abnormal red cell turnover.
Relationship of glucose to HbA 1c
Graphical presentations relating glucose to HbA 1c from the major clinical trials 20, 21 show much variation about the regression lines, indicating that any estimates of one variable from another for use in individuals would have wide CIs and not be exact. Glycation indices show marked inter-individual variation which has not been fully explained. 51 More marked deviation from these linear regression equations would be seen for some of the rare variants mentioned in this paper, but more research is also required in the presence of the more common variant haemoglobins.
Conclusions
Both providers of 'DCCT-aligned' HbA 1c measurements and guideline writers are aware that in some circumstances HbA 1c measurement is not appropriate. This paper provides up-to-date information from manufacturers on the detection of haemoglobin variants by IE HPLC and whether HbA 1c can be reported in patients with variant haemoglobins from other techniques used routinely in the laboratory and POCT. Each provider should determine when HbA 1c reporting from their particular method(s) is not appropriate using the information from the manufacturer/s and current scienti¢c literature, and provide an alternative strategy for monitoring glycaemic Ann Clin Biochem 2006; 43: 135-145 control when necessary. Currently, there is little information on whether glycation rates are a¡ected by the presence of a haemoglobinopathy. Research ascertaining whether the relationship of HbA 1c to blood glucose in patients with variant haemoglobins is similar to published data from the major clinical trials is required as are reference intervals for such patients without diabetes.
